ClinicalTrials.gg
CompletedNCT03745053XLIMITUpdated Feb 7, 2024

XLIMus Drug Eluting Stent: a randomIzed Controlled Trial to Assess Endothelization

An interventional study of Xlimus DES Implantation during coronary angioplasty and Synergy DES Implantation during coronary angioplasty in Coronary Artery Disease, sponsored by Cardionovum GmbH. Completed at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-07.

Sponsored by Cardionovum GmbH · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 208 studies in Coronary Artery Disease with a site in Spain — 39 open to participants now, 66 under way, 6 of them phase 3. Coronary Artery Disease · Spain.

Enrollment
93rd of 136
180 · median 347
Started
2019
with 7 others
No phase
84 of 208
21 open now
Registered
110th of 208
by date

Among the 208 studies in Coronary Artery Disease with a site in Spain, this one is the 93rd largest by enrollment of the 136 interventional ones that give a count, is one of 8 that started in 2019, is one of 84 with no phase, and was the 110th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

39 of the 208 studies in Coronary Artery Disease with a site in Spain are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 208 studies in Coronary Artery Disease with a site in Spain, or all of them as a file.
02

Study summary

The objective of the study is to assess angiographic and clinical performance of Xlimus Drug Eluting Stent (DES) compared to Synergy Bioabsorbable Polymer Everolimus Eluting Stent in patients treated with percutaneous coronary angioplasty

Read the detailed description

The present clinical investigation is designed as a prospective, multicentre, international, randomized, open label, 2-arm parallel group, trial in patients undergoing Percutaneous Coronary Intervention (PCI) comparing Xlimus DES versus Synergy DES with respect to optical coherence tomography (OCT) derived measures at 6-month Follow Up (FU) and clinical events at 12 months after procedure. A total of 180 patients will be recruited and randomized in the two groups in a 2:1 ratio. After index procedure, patients will be followed up by angiographic follow-up at 6 months and clinical follow-up at 12 months.The primary endpoint will be independently evaluated by the Core-Lab which will be blinded as to group assignment

03

Conditions studied

  • Coronary Artery Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age≥18
  2. Documented coronary artery disease (CAD): stable or unstable angina, Non-ST segment MI.
  3. PCI considered appropriate and feasible
  4. Culprit de novo lesion in a native coronary artery with significant stenosis (>50% by visual estimate) eligible for implantation with either study stent (no limitation on the number of treated lesions, vessel and lesion length);
  5. Patient provides written
  6. Patient agrees to all required follow-up procedures and visits.
  7. Target lesion suitable for PCI with DES diameter between 2.5 and 4.0 mm

Exclusion criteria

Exclusion Criteria:

  1. The patient has a known or to any of the following medications: heparin, aspirin, clopidogrel, ticlopidine, sirolimus or its derivatives, everolimus or structurally-related compounds, and/or contrast media (patients with documented sensitivity to contrast which can be effectively pre-medicated with and diphenhydramine [e.g. rash] may be enrolled. Patients with true anaphylaxis to prior contrast media, however, should not be enrolled);
  2. Known hypersensitivity to L605 cobalt chromium, 316L stainless steel, platinum, chromium, iron, nickel or molybdenum;
  3. Known sensitivity to poly-lactic acid or poly(lactic-co-glycolic acid) polymer;
  4. Female of , unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrolment into this study and not using adequate methods;
  5. History of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia), or will refuse blood transfusions;
  6. Previous coronary intervention on target vessel in the 3-months prior to enrollment;
  7. Non-cardiac co-morbid conditions with \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment);
  8. Patients who are actively participating in another drug or device study, which have not completed the primary endpoint follow-up period;
  9. Previously documented (LVEF) \<30%;
  10. Evident cardiogenic shock before randomization;
  11. Patients with left main stem stenosis (>50% by visual estimate);
  12. In-stent restenosis;
  13. ST-segment elevation MI;
  14. Chronic total occlusion/ heavily calcified lesions
  15. Culprit lesion to a Saphenous Vein graft
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    XLIMUS DES

    Xlimus DES Implantation during coronary angioplasty

    Device: Xlimus DES Implantation during coronary angioplasty

  • Active comparator
    Synergy DES

    Synergy DES Implantation during coronary angioplasty

    Device: Synergy DES Implantation during coronary angioplasty

Interventions

  • DeviceXlimus DES Implantation during coronary angioplasty

    Xlimus DES Implantation during coronary angioplasty

  • DeviceSynergy DES Implantation during coronary angioplasty

    Synergy DES Implantation during coronary angioplasty

06

What researchers measure

Primary outcomes

  1. In-stent neointimal volume

    In-stent neointimal volume at 6-month follow-up, measured with OCT, as assessed by the Core-Lab. Neointimal volume will be calculated in all analyzed cross-sections and volumetric measurements and in stent neointimal volume will be compared in the two groups.

    Time frame: 6-month follow-up

Secondary outcomes

  1. Neointimal area

    Neointimal area calculated at the site of minimal lumen area measured with OCT

    Time frame: 6-month follow-up

  2. Number of Target lesion failure

    composite of Cardiac death, target-vessel Myocardial infarction (MI) and clinically indicated target lesion revascularization (TLR)

    Time frame: 12-months follow-up

  3. Number of patients experiencig Cardiac death

    Any death due to proximate cardiac cause (eg, MI, fatal arrhythmia), unwitnessed death and death of unknown cause, and all procedure-related deaths, including those related to concomitant treatment, will be classified as cardiac death

    Time frame: 12-months follow-up

  4. Number of Target-vessel Myocardial infarction

    any MI that, irrespective of the time after the index procedure, is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause. Type of acute MI is classified according to the Joint ESC/ACCF/AHA/ WHF Joint Task Force for the Universal Definition of Myocardial Infarction

    Time frame: 12-months follow-up

  5. Number of Target-lesion revascularization

    repeat revascularization will be defined as any repeat PCI or new coronary artery bypass graft (CABG) surgery within the first year post-PCI

    Time frame: 12-months follow-up

  6. Number of Stent thrombosis

    This is defined according to classification proposed by the Academic Research Consortium

    Time frame: 12-months follow-up

  7. Percentage of Device success at 24 hours

    deployment of the assigned stents without system failure or device-related complication

    Time frame: 24 hours

  8. Percentage of Lesion success at 24 hours

    attainment of \<50% residual stenosis of the target lesion using post-PCI

    Time frame: 24 hours

  9. Percentage of Procedural success at 24 hours

    lesion success without the occurrence of major adverse cardiac event (MACE) during the hospital stay

    Time frame: 24 hours

07

Study locations

4 sites
  • IRCCS Policlinico S. Donato
    San Donato Milanese, Milano 20097, Italy
  • Hospital Bellvitge
    Barcelona, 08025, Spain
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, 08025, Spain
  • Hospital La Paz
    Madrid, 28046, Spain
08

References and documents

Publications

  • Testa L, Squillace M, Ventrella N, Moreno R, Jimenez-Valero S, Serra A, Gomez Hospital JA, Bellamoli M, Popolo Rubbio A, Bedogni F. A randomized control trial to assess optical coherence tomography parameters of the Xlimus drug-eluting stent: the XLIMIT trial. Front Cardiovasc Med. 2023 Sep 6;10:1199475. doi: 10.3389/fcvm.2023.1199475. eCollection 2023. PubMed 37745092 ↗
  • Testa L, Pero G, Bollati M, Casenghi M, Popolo Rubbio A, Cuman M, Moreno R, Serra A, Gomez JA, Bedogni F. XLIMus drug eluting stent: A randomIzed controlled Trial to assess endothelialization. The XLIMIT trial. Int J Cardiol Heart Vasc. 2019 Apr 28;23:100363. doi: 10.1016/j.ijcha.2019.100363. eCollection 2019 Jun. PubMed 31061876 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Sep 2023, 54 months.

Of 177 industry-sponsored interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's 54 months is above that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2018
First posted
Nov 19, 2018
StartActual
Feb 5, 2019
Primary completionActual
Sep 2, 2023
CompletionActual
Sep 2, 2023
Last update
Feb 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03745053
Lead sponsor
Cardionovum GmbH
Collaborators
Mediolanum Cardio Research
Responsible party
Sponsor
First posted
Nov 19, 2018
Start date
Feb 5, 2019
Primary completion
Sep 2, 2023
Completion
Sep 2, 2023
Last update
Feb 7, 2024

Study contacts

Luca Testa, MD
principal investigator · IRCCS Policlinico S. Donato

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion